多替阿巴拉米片要如何使用？

On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation Suimeikai (chemical name:) was officially launched in mainland China. This is the best-selling AIDS drug in the world in the past five years, and it is also an important part of GSK China in the field of AIDS in recent years.

This product should be taken under the guidance of a physician with experience in treating HIV infection.

dose

Adults and adolescents (weighing at least 40 kg)

For adults and adolescents, the recommended dose is one tablet once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given as this product is a fixed-dose tablet and the dose cannot be reduced.

This product is a fixed-dose tablet and should not be used in patients who require dose adjustments. If discontinuation or dose adjustment of one of the active ingredients is necessary, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these drugs.

Miss a dose

If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

elderly patients

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

kidney damage

Patients whose creatinine clearance is less than 50 mL/min are not recommended to take this product.

liver damage

Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment and therefore its use is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible.

children crowd

The safety and effectiveness of this product in children under 12 years of age have not been established. No data yet.

Dosing method

Oral

Can be taken with or without food.